JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) ...

MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA. Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Ente ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to WASHINGTON, D.C. 20549 Commission file number: 001-38556 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ENTERA BIO LTD. (Exact name of Registrant as specified in its charter) For the quarterly period ended March 31, 2025 OR Indicate by check mark whether the registrant is a shell comp ...

Exhibit 99.1 Entera Bio Announces First Quarter 2025 Financial Results and Business Updates JERUSALEM, May 9th 2025 –Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marq ...

JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. “During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. (“OPKO”). EB613 ...

JERUSALEM, April 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman's oral presentation at the 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Congress in Rome entitled "EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY."  EB613 is being developed as th ...

JERUSALEM, April 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman’s oral presentation at the 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Congress in Rome entitled “EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY.” EB613 is being developed as t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ . (State or Other Jurisdiction of Incorporation or Organization) Israel 00-0000000 (I.R.S. Employer Identification No.) Kiryat Hadassah Minrav Building - Fift ...

Exhibit 99.1 JERUSALEM, March 28 2025 –Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024. "2024 was a truly transformational year for Entera. We delivered key data read-outs and advanced each of our oral peptide PTH(1- 34), GLP1/Glucagon and GLP2 tablet programs, significantly increased our stockholder value, and efficiently strengthened our balan ...

Core Insights - Entera Bio Ltd. reported significant advancements in its oral peptide and protein replacement therapies, particularly in osteoporosis and obesity treatments, during 2024 [2][4][12] - The company aims to address unmet medical needs with its innovative N-Tab™ platform, focusing on oral formulations for conditions like osteoporosis, hypoparathyroidism, and short bowel syndrome [12] Financial Performance - For the year ended December 31, 2024, Entera reported a net loss of $9.5 million, or $0.25 per share, compared to a net loss of $8.9 million, or $0.31 per share, for 2023 [11][21] - As of December 31, 2024, the company had cash and cash equivalents of $8.7 million, which increased to $21 million by March 28, 2025, due to investments from institutional shareholders [9] Key Achievements - Entera advanced its EB613 program, the first oral PTH(1-34) tablet treatment candidate for women with osteoporosis, and is preparing for a pivotal Phase 3 study [3][4] - The company also announced the first GLP-1/glucagon agonist peptide tablet candidate for obesity, with promising pharmacokinetic results [5][10] - Entera's collaboration with OPKO Health has been pivotal in developing its oral peptide therapies, including the oral GLP-2 tablets for short bowel syndrome [10][12] Research and Development - Research and development expenses for 2024 were $4.5 million, consistent with the previous year, reflecting ongoing efforts in clinical trials and preparation for future studies [9][21] - The company is focused on innovative approaches to osteoporosis treatment, with the SABRE project under FDA review to qualify bone mineral density as a surrogate endpoint for fractures [3][6] Market Potential - Entera targets a significant market with an estimated 200 million women suffering from osteoporosis, highlighting the need for new treatment options [3] - The company's oral therapies aim to improve patient compliance and address the limitations of current injectable treatments for conditions like short bowel syndrome and obesity [10][12]